Haloperidol is the most frequently used drug to treat delirium in the critically ill patients. Yet, no systematic review has focussed on the effects of haloperidol in critically ill patients with delirium.
| INTRODUC TI ON
Delirium has been reported to affect up to 89% of the critically ill patients and has been associated with poor clinical outcomes including lengthened mechanical ventilation and hospital stay and increased mortality. [1] [2] [3] [4] [5] [6] Furthermore, surviving patients may experience functional decline and long-term cognitive impairment as a consequence of delirium. 6, 7 Haloperidol is the most frequently used pharmacological intervention for delirium treatment in Intensive Care Unit (ICU) settings. [8] [9] [10] [11] The 2002 recommendations of the Society of Critical Care Medicine for clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adults recommended haloperidol as the pharmacological agent for the treatment of delirium (Grade C recommendation, based on case series). 12 However, in the 2013 update of the guideline, this recommendation was changed; haloperidol was no longer recommended due to lack of evidence on the duration of delirium. 13 The latest 2018 update of the same guideline suggests that haloperidol may be used in some delirious cases but not systematically and again the recommendation was graded with low evidence. 14 We have recently demonstrated that current available reviews on delirium management in ICU are of heterogeneous quality with high risk of bias; and we found no systematic reviews as per the PRISMA definitions assessing the effects of haloperidol for the treatment of delirium in ICU. 15 A newly published Cochrane review investigating the effect of pharmacological interventions in critically ill patients with delirium allowed the inclusion of trials with non-delirious patients, however, the trials included patients at risk of developing delirium. 16 As no former systematic review has been conducted on haloperidol for delirium in critically ill patients, fulfilling the PRISMA criteria, 15, 17 with meta-analysis and Trial Sequential Analysis (TSA) 18 our objective was to assess the benefits and harms of haloperidol vs placebo or any intervention for the treatment of delirium in critically ill patients. Our primary comparison was that of haloperidol with placebo. We hypothesized an increase in mortality, serious adverse reactions/events and QTc prolongation; a reduction in delirium duration and severity; and a beneficial effect on health-related quality of life (HRQoL) and cognitive status of haloperidol.
| ME THODS
This systematic review was conducted according to the pre-planned statistical analysis plan of the published protocol. 19 We registered the protocol in the international prospective register of systematic reviews database (PROSPERO) (CRD42017081133), used the methodology of the Cochrane Collaboration 20 and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 17 (Electronic Supplementary Material (ESM)).
| Eligibility criteria
We included randomized clinical trials (RCTs), irrespective of publication status, reported outcomes, publication date and language. Only RCTs with critically ill patients with delirium at trial enrolment were included.
Critical illness included any clinical setting where patients are at high risk of dying or who have actual or potential life-threatening health problems and who are admitted to a high-dependency facility in the hospital, ie an ICU, a coronary care unit or similar facility. We did also include trials on acutely operated patients and elective cardiac surgical patients.
We included any trial comparing haloperidol with placebo, any other pharmacological agent, or combinations of pharmacological and non-pharmacological interventions (single or bundle).
RCTs were excluded if haloperidol was administered in both groups per protocol or if it was administered as a combination therapy with another pharmacological agent.
Our focus was to assess the association between haloperidol and the treatment of delirium (rather than prevention), thus, patients were required to be delirious prior to being randomized to trial drug.
We did not accept agitation alone as an inclusion criterion.
| Outcomes
Our predefined co-primary outcomes were all-cause mortality and proportion of participants with one or more serious adverse reaction (SAR). We used serious as defined by ICH-GCP 21 either as reported by triallists or according to the SAR in the Summary Product Characteristics of haloperidol. Co-secondary outcomes were days alive without delirium within 28 days; HRQoL; cognitive function and delirium severity. We report on QTc prolongation as an exploratory outcome and post hoc analyses on delirium resolution and extrapyramidal symptoms. For all outcomes, we used the trial results reported at the time point closest to 3 months. 
| Search methods

US Food and Drug Administration (FDA); European Medicines
Agency (EMA) and websites of medical companies were searched for unpublished trials. Ultimately, we searched the reference lists of the included trials and previous meta-analyses to identify further relevant trials.
Editorial Comment
There is a need for effective treatments for delirium among critically ill patients. Haloperidol may be one of the more commonly used drugs for this purpose in clinical practice. This trustworthy systematic review presents an analysis of the pooled evidence for the use of haloperidol to treat delirium in patient in the intensive care unit. 
| Trial selection and data extraction
| Risk of bias assessment
MB and SRK independently assessed the risk of systematic errors (bias) of the included trials using the Cochrane Collaboration's risk of bias tool. 20 We specifically assessed the following domains: We planned to assess publication bias, by inspecting funnel plots for signs of asymmetry when ten or more trials were included in an analysis 20, 22 and planned to test for asymmetry with the Harbord test. 23 
| Data synthesis
| Summary measures
Risk ratios (RRs) with 95% confidence intervals (CIs) and CIs adjusted for sparse data, multiple outcomes and testing (TSA adjusted CIs)
were calculated for dichotomous outcomes. For continuous outcomes, end-scores were used, and mean difference (MD) and standardized mean difference (SMD) with CIs and TSA adjusted CIs were planned to be calculated.
| Meta-analysis
We considered the comparison of haloperidol with placebo or with other pharmacological agents in trials not using rescue haloperidol (escape medication) as our primary comparison. We calculated pooled effect estimates using Review Manager. 24 We used a family-wise error rate of 5% 22 and considered a p-value of 0.05/[(2 + 1)/2] = 0.033 or less as statistical significant in the analyses of each co-primary outcome, and we considered a p-value of 0.05/[(3 + 1)/2.5] = 0.025 or less as statistical significant in the analyses of each co-secondary outcome to account for statistical multiplicity due to multiple outcomes. We calculated Bayes factor to assess if the summary effect estimates fitted better with the null hypothesis than alternative hypotheses of the anticipated intervention effects. 22 
| Dealing with missing data
Corresponding authors were contacted to clarify important missing data related to the methods, data reporting or if further trial details were needed (ESM).
We conducted a predefined sensitivity analysis by imputing missing outcome data in a best-worst case scenario and a worst-best case scenario to assess the potential impact of loss to follow-up. 19, 22 
| Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plots, and calculated the inconsistency statistics (I 2 ) and the diversity statistics (D 2 ). 25 We assessed intervention effects with both randomeffects model meta-analyses and fixed-effect model meta-analyses.
We used the more conservative point estimate of the 2, which is the point estimate closest to no effect. If the estimates from the 2 models were approximately equal, we used the estimate with the widest CI. 19, 22 
| Sensitivity analyses and subgroup analyses
We planned to conduct the following predefined subgroup analyses: trials with overall high risk of bias compared to trials with overall low risk of bias and grouping according to patient population, used control intervention in the trials and delirium diagnosis. We conducted a post hoc sensitivity analysis where we included trials using haloperidol as rescue medication.
| Trial Sequential Analysis
We used TSA to assess the risk of random errors due to sparse data, multiple outcomes and multiple testing of accumulating data, 18, [26] [27] [28] [29] [30] [31] [32] [33] [34] and we calculated the required information size. 25 We used a power of 90% (beta 10%) and a diversity 25 as suggested by the trials in the meta-analysis 22 or a diversity of 20% if the measured heterogeneity was zero. 34 As anticipated intervention effects for the primary and secondary outcomes in the TSA, we used a realistic a priori RRR or RRI of 20%.
Furthermore, in a secondary TSA we used a RRR or RRI based on the 95% confidence limit closest to null effect in the traditional meta-analysis. 19 We planned to present 95% CI and TSA adjusted CI. For a more detailed description of the statistical analysis plan and TSA, we refer to the published review protocol. 19 
| Grading certainty of evidence
We used The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach 35 to assess the overall certainty of evidence for all pre-defined outcomes. We appraised the certainty of evidence and our confidence in the effect estimates based on risk of bias, inconsistency, indirectness, imprecision and publication bias. Thus, we rated the overall certainty of evidence as high, moderate, low or very low.
| RE SULTS
| Study selection
We identified 5392 references and included 8 RCTs 36-43 with 11 comparisons ( Figure 1 ) and a total of 951 participants. We listed reasons for exclusion of key excluded trials, which included 33 RCTs of haloperidol for the treatment of delirium in patients not being critically ill and 5 RCTs due to wrong indications (ESM). In addition, we identified 4 ongoing trials 44-47 and 8 terminated trials [48] [49] [50] [51] [52] [53] [54] [55] with no results (ESM).
| Characteristics of included trials
The included trials were published between 1996 and 2018 (Table 1) .
Seven trials were published as full trial reports and one trial published its results on clinicaltrials.gov. The 8 included trials covered 11 comparisons, of which the control group was placebo in 2, 39,41 dexmedetomidine in 1, 37 morphine in 1, 36 benzodiazepine (lorazepam) in 1, 38 ondansetron in 2 37, 43 and antipsychotics (chlorpromazine, ziprasidone, risperidone, olanzapine) in 4. [38] [39] [40] 42 Three trials used haloperidol as rescue medication. 37, 39, 42 All trials included adult critically ill patients. Five trials included adults admitted to an ICU, 37,39-42 2 trials included cardiac surgical patients 36, 43 and 1 trial included medical patients. 38 Details and additional information of the included trials are presented in the ESM.
The number of participants in the trials ranged from 24 to 566.
Mean age of participants ranged from 31 years to 71 years and proportion of men ranged between 54% and 91% in the included trials.
| Risk of bias
We adjudicated 1 trial as having overall low risk of bias; the remaining 7 had overall high risk of bias ( Figure 2 ).
| Effect of interventions
| All-cause mortality
Four of 8 trials (6 comparisons) 36, 38, 39, 41 with a total of 678 participants and a mean follow-up of 34 days (range 8 to 90 days) reported on all-cause mortality. One trial was overall low risk of bias and included 566 participants. Two trials were placebo-controlled trials.
One trial used haloperidol as rescue drug. Meta-analysis, regardless of risk of bias, showed no evidence of a difference in haloperidol vs control for the treatment of delirium when assessing mortality (fixed effect model RR 1.01;
95% CI 0.33-3.06; I 2 = 0%; 112 participants; 3 trials; 4 comparisons; Figure 3 ). The certainty of evidence, using the GRADE approach, was very low due to serious risk of bias, indirectness and imprecision ( Table 2) .
As only 1% of the required information size had been reached, TSA adjusted CI could not be calculated. Bayes Factors are presented in the ESM.
The sensitivity analyses on missing data indicated that incomplete outcome data alone had the potential to influence the results: 
| Serious adverse reactions
Four trials (5 comparisons) reported on the proportion of patients with serious adverse reactions/events, 36, 37, 40, 41 although none defined the adverse reactions/events according to ICH-GCP. All 4 trials reported zero events in each group despite reporting on mortality. Only one trial reported on individual
SAEs. 41 The certainty of evidence was judged to be very low due to serious risk of bias, inconsistency, indirectness and imprecision ( Table 2 ).
| Days alive without delirium within 28 days
One trial with overall low risk of bias 39 
| Quality of life
None of the included trials reported any data on quality of life.
| Cognitive function
One overall high risk of bias trial 38 
| Severity of delirium
Five overall high risk of bias trials 37, 38, 40, 42, 43 (7 comparisons; comparing haloperidol with dexmedetomidine in 1, ondansetron in 2, antipsychotics in 3 and benzodiazepine in 1) reported on delirium severity. Two trials used ICDSC, 37,42 1 trial used delirium rating scale, 38 1 trial used Memorial Delirium Assessment Scale 40 and 1 trial used a 4 point mental scoring scale. 43 No trials were placebo-controlled and 2 trials used haloperidol as rescue drug. 37, 42 Meta-analysis, regardless of risk of bias, showed no evidence of a difference in haloperidol vs control for the treatment of delirium Figure 4 ). The certainty of evidence was judged to be very low due to serious risk of bias, inconsistency, indirectness and impression ( Table 2 ).
The TSA program does not facilitate meta-analysis of SMDs.
SMDs was used because the mean response was not measured on the same scale. We decided not to convert scores into the frequently used scale as 3 different scales (in 3 trials) were used.
For the same reason, analyses were not conducted within trials using the same scale. Bayes factor is not possible to calculate from SMD.
The sensitivity analyses on missing data indicated that incomplete outcome data did not have the potential to influence the results (best-worst case scenario and worst-best case scenario (ESM). 
| QTc prolongation
Three trials, 37, 39, 41 of which 1 was overall low risk of bias (5 comparisons; comparing haloperidol with placebo in 2, antipsychotics in 2 and dexmedetomidine in 1), reported on QTc prolongation. Two trials used rescue haloperidol. 37, 39 In the trial not using rescue haloperidol, a total of 18.8% of the participants in the haloperidol group vs 7.8% of the participants in the control group had QTc prolongation. The certainty of evidence was very low due to serious risk of bias, indirectness and imprecision ( 
| Post hoc analyses
Post hoc analyses on delirium resolution and extrapyramidal symptoms showed no evidence of a difference of haloperidol vs control for the treatment of delirium when assessing delirium resolution and extrapyramidal symptoms (ESM). of evidence to support or refute the use of haloperidol for the treatment of delirium in critically ill patients. The TSA showed that only 1% of the required information size to detect or reject a 20% RRR or RRI in mortality was accrued and 11.237 patients probably need to be randomized before firm conclusion can be drawn for the effect on mortality. The effects on serious adverse reactions/events, days alive without delirium, quality of life, cognitive function, delirium severity and QTc prolongation were also inconclusive due to sparse or no data. Thus, the use of haloperidol as the preferred drug to treat delirium in critically ill patients lacks evidence from RCTs.
| D ISCUSS I ON
| Strengths and limitation
Strengths of this review include the systematic, transparent and robust methodology used, including a pre-published protocol, 19 the use of Cochrane methodology, 20 reporting as per the PRISMA statement, 17 an up-to-date comprehensive literature search, and the independent study selection, data extraction and risk of bias assessment by 2 authors. Also, we used TSA to assess the overall risk of random error to increase the reliability of the results of the metaanalysis, and to identify the required information size. Finally, we assessed the certainty of evidence using GRADE. although mortality was reported. Accordingly, serious adverse reactions/events are likely to be considerably underreported. Finally, sparse data on all reported outcomes resulted in no firm evidence on the balance between the benefits and harms for these outcomes.
Limitations
| Our results in relation to previous reviews
Previous reviews on the treatment of delirium in critically ill patients have been shown not to be systematic according to PRISMA guideline. 15 Besides methodological weaknesses, a common problem with the previous reviews are the inclusion of trials of both prevention (including trials of patients being enrolled regardless of delirium status at enrolment) and treatment of delirium. Furthermore, trials may have been missed and not included and a clear-cut definition of the patient population has often not been adequately described or discussed; for example we decided to exclude the trial by Reade et al, 56 which included patients with delirium or agitation, as only 30/40% of the participants had delirium at enrolment. Several reviews on either delirium prevention or treatment in all hospitalized patients have been published. However, only a few reviews focusing on delirium treatment in the critically ill patients have been published, and these also found no evidence of effect of haloperidol on the studied outcomes. 16, [57] [58] [59] Other reviews report on length of ICU and hospital stay, and apart from being biased and not patient centred outcomes such data are not normally distributed and, thus, should not be meta-analysed.
A Cochrane review on antipsychotics for the treatment of delirium in hospitalized patients, however, with the exclusion of ICU patients, did not find evidence for a difference on any of the studied outcomes. 60
| Clinical implications and perspectives
Many critically ill patients develop delirium and haloperidol is still the most commonly used pharmacological intervention. 8 In this systematic review, we did not find evidence of neither a beneficial nor a harmful effect of the use of haloperidol and the uncertainty of its effects remains high.
Currently 4 randomized clinical trials are recruiting patients, but especially the AID-ICU trial 46 and the EuRIDICE trial 47 comparing haloperidol with placebo aiming to reach a combined total of 1742 participants will contribute a higher certainty of evidence.
Nevertheless, true placebo-controlled trials, using other rescue drugs than haloperidol, reporting on patient-centred outcomes such as all-cause mortality, days alive without delirium, serious adverse reactions/events, HRQoL and cognitive status on delirium treatment are urgently needed.
The lack of evidence on the use of haloperidol for the treatment of delirium challenges the clinicians managing these patients.
In spite of the low certainty, we still need to systematically screen and identify critically ill patients with delirium and haloperidol may still be included in the treatment when prevention and non-pharmacological interventions have failed as suggested in the updated guidance. 14,61
| CON CLUS IONS
The evidence for the use of haloperidol to treat critically ill patients with delirium is sparse, of low quality and inconclusive. We therefore have no certainty regarding any beneficial, harmful or neutral effects of haloperidol in these patients. We therefore need many more patients randomized into trials with overall low risk of bias not using haloperidol as rescue drug, to ensure the safety of critically ill patients with delirium.
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